BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

  1. Homepage
  2. Medicinal products
  3. Pharmacovigilance
  4. Risk information

Direct Healthcare Professional Communication (DHPC) on metamizole: risk of drug-induced liver injury

2020.12.15

Active substance: metamizole

The marketing authorisation holders of metamizole-containing medicinal products in agreement with the European Medicines Agency (EMA) and the Federal Institute for Drugs and Medical Devices (BfArM) would like to inform you that cases of drug-induced liver injury (DILI) with metamizole have been reported.

Download DHPC / Information letter , Download_VeroeffentlichtAm_EN PDF, 212KB, File is accessible